Home \ Cardiology \ Comorbid Patient

Comorbid patient

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:45
Recommendations of komorbid pathology
01:21
The difference between polymorbid and comorbid pathology
03:00
Charleson Comorbus Evaluation
04:30
Comorbidity phenotypes in age -related patients
05:09
Arterial hypertension and chronic brain ischemia
05:52
Polypragmasis, risks and ways to avoid
14:49
Evidence of neurocytoprotectors medicine
16:02
Mexidol® - Studies of efficiency and safety
16:41
Mexidol® - efficiency and subanalism by age groups

Ostroumova Olga Dmitrievna – Doctor of Medical Sciences, Professor, Head. Department of Therapy and Polymorbid Pathology named after. Academician M.S. Vovsi FSBEI DPO RMANPE Ministry of Health of Russia

Anton Pavlovich Pereverzev – PhD, Associate Professor of the Department of Therapy and Polymorbid Pathology of the Federal State Budgetary Educational Institution of Higher Professional Education, Russian Medical Academy of Postgraduate Education, Ministry of Health of the Russian Federation

Announcement:

There are many terms in the literature to describe a combined pathology. However, the key difference is the presence of a pathogenetic connection between diseases. If several diseases are pathogenetically interconnected, then this is comorbidity. With polymorbidity, the disease can be both pathogenetically or not related - this is a broader concept. It is very important to avoid polypragmasis in the therapy of comborbid patients, for this we need to optimize the drug therapy scheme, as well as the use of multimodal drugs.

All videos Next video

The brain in focus of arterial hypertension

Peculiarities of managing elderly patients

The brain is a key target organ for treatment of cerebrovascular risks

Mexidol as a geroprotector: potential and prospects

Neuroprotection in arterial hypertension and cognitive impairment

The Connection Between Vascular Diseases of the Brain and Eye: A Neurologist and Ophthalmologist's Perspective

Ischemic stroke: clinical guidelines and practical aspects

NIHSS and mRS: Gold Standards in Neuroscience

Cognitive impairment caused by arterial hypertension: from clinical guidelines to practical algorithms

The brain is a target organ for arterial hypertension: features of management of the elderly patient

Time codes:

00:45
Recommendations of komorbid pathology
01:21
The difference between polymorbid and comorbid pathology
03:00
Charleson Comorbus Evaluation
04:30
Comorbidity phenotypes in age -related patients
05:09
Arterial hypertension and chronic brain ischemia
05:52
Polypragmasis, risks and ways to avoid
14:49
Evidence of neurocytoprotectors medicine
16:02
Mexidol® - Studies of efficiency and safety
16:41
Mexidol® - efficiency and subanalism by age groups

Block of articles on this topic

The influence of Mexidol on the improvement of cognitive status and quality parameters as part of the complex therapy of patients with chronic heart failure of the II - III functional class

Author:
TOLKACHEVA V.V., KARAPETYAN L.V., KHUTSISHVILI N.I., GALOCHKIN S.A., KAZAKHMEDOV E.R., KOBALAVA Zh.D.

FGAOU in Russian University of Friendship of Peoples named after Patrice Lumumba, Moscow, Russia

The effectiveness of Mexidol® in patients with neurological complications of type 2 diabetes

Author:
E.L. PUGACHEVA

FSBEI in "First St. Petersburg State Medical University named after Acad. I.P. Pavlova "of the Ministry of Health of Russia, St. Petersburg, Russia

Mexidol® and Mexidol® Fort 250 as part of the sequential therapy for cognitive disorders in comorbide patients with joint pathology against the background of arterial hypertension and coronary heart disease

L.N. Eliseeva, S.V. Kartashova

FSBEI in Kuban State Medical University of the Ministry of Health of Russia, Krasnodar

The influence of Mexidol on the quality of life and the functional status of patients with chronic ischemia of the brain and chronic heart failure with a low emission fraction

Authors:
V.V. TOLKACHEVA¹, E.R. KAZAKHMEDOV¹, J.D. KOBALAVA¹, S.A. GALOCHKIN¹, A.V. SHCHULKIN²

¹Peoples' Friendship University of Russia, Moscow, Russia;
²Ryazan State Medical University named after Academician I.P. Pavlov of the Ministry of Health of the Russian Federation, Ryazan, Russia

The effectiveness of the use of ethylmethylhydroxypyridine of succinate in patients with cerebrovascular pathology against the background of diabetes and metabolic syndrome

Authors:
E.V. EKUSHEVA^1,2, E.V. BIRYUKOVA³

¹Federal State Budgetary Institution "Academy of Postgraduate Education "Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency", Moscow, Russia;
²Belgorod State National Research University, Belgorod, Russia;
³A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation, Moscow, Russia

THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

Source of photos and images Shutterstock.com